Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders

A Multicentric, Retrospective, Real-Word Study to Evaluate the Efficacy and Safety of Inebilizumab Compare With Rituximab in Neuromyelitis Optica Spectrum Disorders

To compare the safety and efficacy of Inebilizumab and Rituximab in neuromyelitis optica spectrum disorders (NMOSD) patients.

Study Overview

• Status: Not yet recruiting
• Conditions: Neuromyelitis Optica Spectrum Disorders
• Intervention / Treatment: Drug: Inebilizumab; Drug: Rituximab(RTX)

Detailed Description

Inebilizumab is a humanized anti-CD19 monoclonal antibody. CD19 is broadly expressed on B-lineage cells, particularly late-stage memory B-lymphocytes and plasma blasts. Inebilizumab depletes antibody-secreting plasmablasts and some plasma cells.

Rituximab (RTX) is a chimeric anti-CD20 monoclonal antibody that promotes B-lymphocyte depletion through antibody-dependent cellular cytotoxicity (ADCC)/complement-dependent cytotoxicity (CDC), promotes an immunoregulatory T-lymphocyte phenotype, and activates neutrophil/macrophage phagocytosis.

This is a retrospective, multicentre, real-world study which aims to compare Inebilizumab with RTX in neuromyelitis optica spectrum disorders patients. Eighty patients from 8 centres in China will be enrolled.

• Study Type: Observational
• Enrollment (Estimated): 80

Contacts and Locations

• Study Contact: Name: Jinzhou Feng, Ph.D; Phone Number: 023-89012487; Email: 203756@cqmu.edu.cn

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients with Neuromyelitis Optica Spectrum Disorders

Description

Inclusion Criteria:

• 1. Age ≥ 18 years with anti-AQP4-IgG seropositive NMOSD as defined by 2015 NMOSD diagnostic criteria by IPND (International Panel for NMO Diagnosis).
• 2. Expanded disability status scale (EDSS) score ≤ 8 and ≥ 2.5 during the acute phase.
• 3. Patients have given their written informed consent.

Exclusion Criteria:

• 1. Lactating and pregnant females.
• 2. Participate in other interventional studies within 30 days or within 5 half-lives of the investigational agent before received inebilizumab and rituximab (RTX).
• 3. Receipt of any experimental B-cell depleting agent within 6 months prior inebilizumab and RTX, and B-cells below the lower limit of normal
• 4. Known history of a severe allergy or reaction to any component of the investigational product formulation.
• 5. Known active severe bacterial, viral, or other infection or any major episode of infection requiring hospitalization (including viral hepatitis, active tuberculosis or positive tuberculosis screening).
• 6. History of alcohol, drug, or chemical abuse, or a recent history of such abuse < 1 year prior to treatment.
• 7. History of malignancies.
• 8. Combined with severe mental disorders and other conditions and unable to cooperate with follow-up.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Exposed group 1; Intravenous methylprednisolone (IVMP) plus Inebilizumab	Drug: Inebilizumab; Inebilizumab: 300mg IV on Day1 and Day 15. The first dose of inebilizumab was given after IVMP.
Exposed group 2; IVMP plus Rituximab (RTX)	Drug: Rituximab(RTX); RTX: 500mg IV on Day 1 and Day15. The first dose of RTX was given after IVMP.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Expanded Disability Status Scale Score (EDSS) from baseline.	Change in Expanded Disability Status Scale (EDSS) score from baseline to 12 months after treatment (EDSS: Minimum Score 1, Maximum score 10, higher scores mean a worse outcome).	12 months
Time to first relapse	Relapse: A monophasic clinical episode with patient-reported symptoms and objective findings reflecting a focal or multifocal inflammatory demyelinating event in the central nervous system (CNS), developing acutely or subacutely, with a duration of at least 24h, without fever or infection.	12 months
Number of new, and/or enlarging T2- hyperintense lesions detected by Magnetic Resonance Imaging (MRI)	Number of new, and/or enlarging T2-hyperintense lesions detected by Magnetic Resonance Imaging (MRI) at the last visit.	12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Expanded Disability Status Scale (EDSS) score from baseline	Change in Expanded Disability Status Scale (EDSS) score from baseline at month 6 (EDSS: Minimum Score 1, Maximum score 10, higher scores mean a worse outcome).	6 months
Percentage of Participants with Disability Improvement	Disability improvement is defined as a reduction in EDSS score of: A) >=1.0 from the baseline EDSS score when the baseline score was <=5.5 B) >= 0.5 when the baseline EDSS score > 5.5(EDSS: Minimum Score 1, Maximum score 10, higher scores mean a worse outcome).	12 months
Percentage of Participants with Disability Worsening	A participant was considered to have a worsening in overall EDSS score of at least 2 if baseline EDSS score was 0, or at least 1 point if baseline EDSS score is 1 to 5, or at least 0.5 point if baseline EDSS score is 5.5 or more.	12 months
Change in modified Rankin score (mRS) from baseline	Change in modified Rankin score (mRS) from baseline at month 12(mRS: Minimum Score 0, Maximum score 6, higher scores mean a worse outcome).	12 months
Change in Timed 25 Foot Walk Test from baseline	Change in time taken to complete the timed 25foot walk test from baseline	12 months
Number of NMOSD attacked related rescue treatment.		12 months
Annual relapse rate (ARR) before and after Inebilizumab/Rituximab	ARR will be measured in the baseline (according to patients' history before inebilizumab/rituximab) and after 12 months of intervention.	12 months
Change in serum glial fibrillary acidic protein antibody (GFAP-Ab) levels from baseline.	Change in serum GFAP-Ab levels from baseline at the last visit	12 months
Change in aquaporin 4 antibody (AQP4-Ab) titers from baseline.	Change in AQP4-ab titers from baseline at the last visit.	12 months
Change in serum Neurofilament light chain protein (NfL) levels from baseline.	Change in serum NfL levels from baseline at the last visit.	12 months
Change in Visual Acuity (VA) from baseline	Change in Visual Acuity (VA) at month 12.	12 months
Changes in The Five Level of EuroQol Five Dimensions Questionnaire (EQ-5D-5L) scores from baseline	Changes in EQ-5D scores from baseline at month 12(EQ-5D-5L: Minimum Score 5, Maximum score 25, lower scores mean a better quality of life).	12 months
Change in retinal nerve fiber layer (RNFL) loss from baseline	Change in retinal nerve fiber layer (RNFL) loss measured by optical coherence tomography (OCT) from baseline at month 12.	12 months
Adverse reactions during treatment and follow-up		12 months

Collaborators and Investigators

• Sponsor: Feng Jinzhou
• Investigators: Principal Investigator: Jinzhou Feng, Ph.D, First Affiliated Hospital of Chongqing Medical University

Study record dates

Study Major Dates

• Study Start (Estimated): October 20, 2023
• Primary Completion (Estimated): June 30, 2024
• Study Completion (Estimated): June 30, 2025

Study Registration Dates

• First Submitted: September 29, 2023
• First Submitted That Met QC Criteria: September 29, 2023
• First Posted (Actual): October 5, 2023

Study Record Updates

• Last Update Posted (Actual): October 5, 2023
• Last Update Submitted That Met QC Criteria: September 29, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Keywords: Rituximab; Neuromyelitis Optica Spectrum Disorders; Inebilizumab
• Additional Relevant MeSH Terms: Nervous System Diseases; Immune System Diseases; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Demyelinating Diseases; Autoimmune Diseases; Eye Diseases; Optic Nerve Diseases; Cranial Nerve Diseases; Myelitis, Transverse; Optic Neuritis; Neuromyelitis Optica; Physiological Effects of Drugs; Antirheumatic Agents; Antineoplastic Agents; Immunologic Factors; Antineoplastic Agents, Immunological; Rituximab
• Other Study ID Numbers: IRNMO-001

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No